Cencora, Inc. (COR) reported first-quarter fiscal 2024 adjusted earnings per share (EPS) of $3.28, which beat the Zacks Consensus Estimate of $2.86 by 14.7%. The bottom line also improved 21% year over year.GAAP EPS was $2.98, up 27.9% from that reported in the year-ago period.Revenue DetailsRevenues totaled $72.3 billion, up 15% year over year. The top line beat the Zacks Consensus Estimate by 5.1%.Segmental AnalysisU.S. Healthcare SolutionsRevenues in this segment totaled $65.2 billion, up 15.9% on a year ...

Cencora (COR) came out with quarterly earnings of $3.28 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $2.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.69%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $2.79 per share when it actually produced earnings of $2.86, delivering a surprise of 2.51%.Over the last four quarters, ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Cencora (COR) , which belongs to the Zacks Medical Services industry.This prescription drug distributor has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 2.84%.For the last reported quarter, Cencora came out with earnings of $2.86 pe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 CENCORA, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 23-30 ...

Wall Street analysts expect Cencora (COR) to post quarterly earnings of $2.85 per share in its upcoming report, which indicates a year-over-year increase of 5.2%. Revenues are expected to be $68.81 billion, up 9.5% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company reveals its earnings, it is vital to take into acco ...

Have you been paying attention to shares of Cencora (COR) ? Shares have been on the move with the stock up 7.5% over the past month. The stock hit a new 52-week high of $221.31 in the previous session. Cencora has gained 6.3% since the start of the year compared to the -1% move for the Zacks Medical sector and the -7% return for the Zacks Medical Services industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus e ...

UNITED STATES ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark if the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Act). Yes þ No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ...

Cencora, Inc. (NYSE:COR) Q4 2023 Results Conference Call November 2, 2023 8:30 AM ET Company Participants Bennett Murphy - SVP, Head IR and Treasury Steve Collis - Chairman, President and CEO Jim Cleary - EVP and CFO Conference Call Participants Lisa Gill - JPMorgan Elizabeth Anderson - Evercore ISI Eric Percher - Nephron Research Daniel Grosslight - Citibank Allen Lutz - Bank of America George Hill - Deutsche Bank Andrea Alfonso - UBS Charles Rhyee - TD Cowen Erin Wright - Morgan Stanley Operator Hello, ev ...

AmerisourceBergen Corporation (ABC) Q3 2023 Earnings Call Transcript August 2, 2023 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR and Treasury Steve Collis - Chairman, President and CEO Jim Cleary - EVP and CFO Conference Call Participants Elizabeth Anderson - Evercore ISI Lisa Gill - JP Morgan Eric Percher - Nephron Research Daniel Grosslight - Citi Charles Rhyee - TD Cowen Kevin Caliendo - UBS Eric Coldwell - Baird Jonathan Young - Credit Suisse Dan Clark - Bank of America George Hill - ...

Q3 FY2023 Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as aim," "anticipate," "believe," "can," "continue," "could,", "estimate," "expect," "intend," "may," "might," "on track," "opportunity," "plan," "possible," "potential," "predict," "project," "seek," "should," "strive," "su ...